SCHEMBL15057461

SCHEMBL15057461

Cc1c(O)ccc2nccc(Cl)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 3/20 0.40
MAPKAPK2 P49137 2/20 0.35
KDM4E B2RXH2 3/20 0.33
HSP90AA1 P07900 2/20 0.33
MAPT P10636 2/20 0.33
BRD4 O60885 1/20 0.33
LMNA P02545 1/20 0.33
METAP2 P50579 1/20 0.33
METAP1 P53582 1/20 0.33
RET P07949 1/20 0.32
KIF5B P33176 1/20 0.32
MEN1 O00255 3/20 0.31
KMT2A Q03164 3/20 0.31
ESR1 P03372 1/20 0.31
ESR2 Q92731 1/20 0.31
ERN1 O75460 1/20 0.31
MAPK1 P28482 2/20 0.30
CYP3A4 P08684 1/20 0.30
ALDH1A1 P00352 2/20 0.30
GAA P10253 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30629503 0.82 HCAR1 (0.33) TLR8KDM4EMAPTMEN1KMT2A
SCHEMBL25243515 0.78 TLR8 (0.34) TLR8MAPKAPK2KDM4EHSP90AA1MAPT
SCHEMBL15056561 0.78 CYP17A1 (0.38) TLR8MAPKAPK2KDM4EHSP90AA1MAPT
SCHEMBL17212936 0.70 KDM4E (0.53) TLR8KDM4EHSP90AA1MAPTBRD4
SCHEMBL6004107 0.70 NR4A2 (0.34) KDM4EMAPTMEN1KMT2AMAPK1
SCHEMBL8603889 0.69 PARP1 (0.44) KDM4EMAPTMEN1KMT2AMAPK1
SCHEMBL7461243 0.69 PARP1 (0.44) KDM4EHSP90AA1MAPTBRD4LMNA
SCHEMBL24715874 0.68 KDM4E (0.55) KDM4EHSP90AA1MAPTBRD4LMNA
SCHEMBL27381846 0.67
SCHEMBL15108807 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150148377-A1 Quinoline Derivatives NOVARTIS AG (CH) 2015-05-28 US disclosed
US-20150148377-A1 Quinoline Derivatives NOVARTIS AG (CH) 2015-05-28 US disclosed
US-20150148377-A1 Quinoline Derivatives NOVARTIS AG (CH) 2015-05-28 US disclosed
EP-2794594-A1 QUINOLINE DERIVATIVES Novartis AG (CH) 2014-10-29 EP disclosed
WO-2013093850-A1 QUINOLINE DERIVATIVES NOVARTIS AG (CH) 2013-06-27 WO disclosed
WO-2013093850-A1 QUINOLINE DERIVATIVES NOVARTIS AG (CH) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148377-A1 Quinoline Derivatives RECQL, NQO2, PIK3R3 TLR8 3989/4885MAPKAPK2 1543/4885KDM4E 2816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.